0001415889-24-014781.txt : 20240529
0001415889-24-014781.hdr.sgml : 20240529
20240529170017
ACCESSION NUMBER: 0001415889-24-014781
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240524
FILED AS OF DATE: 20240529
DATE AS OF CHANGE: 20240529
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pooler Amy
CENTRAL INDEX KEY: 0002001413
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 24999404
MAIL ADDRESS:
STREET 1: C/O SANGAMO THERAPEUTICS, INC.
STREET 2: 7000 MARINA BLVD.
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 501 CANAL BLVD.
CITY: RICHMOND
STATE: CA
ZIP: 94084
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD.
CITY: RICHMOND
STATE: CA
ZIP: 94084
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
form4-05292024_090511.xml
X0508
4
2024-05-24
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0002001413
Pooler Amy
C/O SANGAMO THERAPEUTICS, INC.
501 CANAL BLVD.
RICHMOND
CA
94084
false
true
false
false
VP, HEAD OF RESEARCH
0
Common Stock
2024-05-24
4
F
0
702
0.60
D
195612
D
Common Stock
2024-05-25
4
F
0
493
0.60
D
195119
D
Represents shares underlying the portions of RSU grants that vested on May 24, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 24, 2024 of $0.60/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
Includes: (a) 1,319 shares resulting from the May 24, 2024 vesting installment of the Reporting Person's February 24, 2023 RSU grant, and the remaining 14,151 shares will vest in successive equal quarterly installments through February 24, 2026, (b) 5,672 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025 and (c) 150,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter.
The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Represents shares underlying the portions of RSU grants that vested on May 25, 2024, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 24, 2024 of $0.60/share, pursuant to the terms of the 2018 EIP. This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
Includes: (a) 925 shares resulting from the May 25, 2024 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 4,254 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 14,151 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 150,000 shares subject to the Reporting Person's January 22, 2024 RSU grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter.
/s/ Ron A. Metzger, Attorney-in-Fact
2024-05-29